Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9587424 | 0.80 | BCHE (0.37) | POLBSMN1; SMN2MAPK1BCHENPC1 | |
| SCHEMBL1642678 | 0.79 | DAO (0.39) | SMN1; SMN2TSHRNPC1RAB9AHSD17B10 | |
| SCHEMBL20138330 | 0.75 | RAB9A (0.50) | SMN1; SMN2TSHRP2RX4MAPTNPC1 | |
| SCHEMBL5788693 | 0.74 | NOTUM (0.47) | POLBMAPK1TP53TSHRMAPT | |
| SCHEMBL4919212 | 0.73 | L3MBTL1 (0.41) | POLBSMN1; SMN2MAPK1TSHRCYP2C19 | |
| SCHEMBL28702886 | 0.70 | TSHR (0.57) | SMN1; SMN2MAPK1TP53EPHX1TSHR | |
| SCHEMBL1573833 | 0.68 | ASAH1 (0.56) | SMN1; SMN2MAPK1TP53MAPTNPC1 | |
| SCHEMBL17022591 | 0.68 | PDGFRB (0.50) | POLBSMN1; SMN2MAPK1TP53EPHX1 | |
| SCHEMBL289936 | 0.67 | NR1H2 (0.42) | BCHE | |
| SCHEMBL1643083 | 0.65 | HPGD (0.44) | POLBTSHREPHX2BCHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2185541-B1 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | disclosed |
| US-8853406-B2 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| EP-2001868-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-17 | — | — | EP | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8377961-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-8232298-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | LACRAMPE JEAN FERNAND ARMAND (FR) | 2012-03-22 | — | — | US | disclosed |
| US-8088795-B2 | Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| EP-2185541-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090149493-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN-CILAG (FR) | 2009-06-11 | — | — | US | disclosed |
| WO-2009019274-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-12 | — | — | WO | disclosed |
| EP-2001868-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1999126-A1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | Janssen Pharmaceutica, N.V. (BE) | 2008-12-10 | — | — | EP | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007107545-A1 | CYCLIC-ALKYLAMINEDERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107543-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1809622-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071508-A1 | CYCLIC-ALKYLAMINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | POLB 573/4885SMN1; SMN2 4593/4885MAPK1 1558/4885 |
| US-20090149493-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | POLB 1084/4885SMN1; SMN2 3540/4885MAPK1 1743/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | POLB 1555/4885SMN1; SMN2 3698/4885MAPK1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.